ArticlePloS one2026
Evaluation of pre-Omicron population immunity for SARS-CoV-2 in the Household Influenza Vaccine Evaluation (HIVE) cohort.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal antibody correlates of SARS-CoV-2 infection in a US household cohort during Omicron waves.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinued serosurvey for SARS-CoV-2 population immunity is critical for vaccine strain selection and identification of susceptible groups such as young children. We aim to evaluate the use of a high-throughput, low-volume assay to describe strain-specific IgG measurement in a longitudinally followed community based cohort.
methodsThe longitudinal Household Influenza Vaccine Evaluation study has observed around 300 households annually for acute respiratory illness. SARS-CoV-2 variant-specific IgG (including original, Delta, Beta, and Omicron variants) concentrations were measured using multiplex electrochemiluminescence (ECL), pseudoviral neutralization (PN), and ACE2 inhibition assays in participants who had serum samples drawn between July 1 and December 31, 2021. Spearman's rank correlation coefficient assessed correlation within and between ECL, ACE2, and PN assays. Receiver operating characteristic (ROC) analysis evaluated the performance of ECL and ACE2 assays. Generalized additive mixed models estimated population immunity by age against SARS-CoV-2 variants.
resultsA total of 156 serum samples from 117 participants were selected for this study. Most (65.8%) were from adults and a majority (77.8%) received vaccination during the analysis period. High correlations were observed within ECL IgG assays (0.95-1.00), within ACE2 inhibition assays (0.70-0.99), and between assay platforms, including ECL versus PN (0.81-0.83) and ACE2 versus PN (0.88-0.95). ROC analysis demonstrated strong discrimination of vaccination status by ECL IgG assays (AUC: 0.84-0.88; sensitivity: 0.88-0.91; specificity: 0.87-0.88). ACE2 inhibition assays showed more variable performance (AUC: 0.53-0.96; sensitivity: 0.17-0.93; specificity: 0.91-1.00), with lower performance observed for some BA.2-related antigens. SARS-CoV-2 IgG concentrations generally increased with age and appeared to plateau in early adulthood, although estimates were imprecise in younger age groups because of small sample sizes.
conclusionWe found a high correlation between ECL, ACE2, and PN across variants. Age-specific IgG quantities reflected behavior and infection histories collected by active surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.